4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Current Quarter	$-0.53	Next Quarter	$-1.05
Current Year	$-3.23	Next Year	$-3.4
QoQ Growth	-98.1%	YoY Growth	-5.3%
3Y EPS CAGR	-5.1%	Target Price	$33.11
Consensus	Buy	Upside	+205.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FDMT	$10.84	-0.73%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FDMT	$10.84	-0.7%	1.02M
3
4
5
6

FDMT

FDMT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get 4D Molecular Therapeutics Inc. Data in Excel

Get 4D Molecular Therapeutics Inc. Data in Excel